Refractory coccidioidomycosis treated with posaconazole

Gregory M. Anstead, Gavin Corcoran, James Lewis, Deborah Berg, John R. Graybill

Research output: Contribution to journalArticle

104 Scopus citations

Abstract

Background. Disseminated coccidioidomycosis (which is caused by the endemic fungi of the genus Coccidioides) can be a life-threatening systemic fungal infection. Although conventional antifungal therapies have activity against Coccidioides, the disease can be refractory to standard therapies. Drug-associated toxicities also may limit the clinical utility of the standard antifungal drugs. In addition, relapses in patients with disseminated coccidioidomycosis are common, making long-term management of this disease challenging. Methods. We report the outcomes of 6 patients with coccidioidomycosis who were treated with posaconazole salvage therapy after treatment with conventional antifungal therapies failed to produce sustained clinical improvement. Patients were administered posaconazole oral suspension 800 mg/day in divided doses as part of an open-label clinical trial. A modified version of the Mycoses Study Group Coccidioides scoring system was used to evaluate the burden of disease. Posaconazole therapy resulted in rapid clinical improvements in the signs and symptoms of coccidioidomycosis. Results. At the end of therapy, 5 of 6 patients had successful outcomes. Posaconazole was well tolerated despite long-term administration (1-2 years), and 2 patients continued to receive posaconazole maintenance therapy at the time of writing. Conclusions. The successful outcomes observed in this case series suggest that posaconazole is an effective therapy for coccidioidomycosis.

Original languageEnglish (US)
Pages (from-to)1770-1776
Number of pages7
JournalClinical Infectious Diseases
Volume40
Issue number12
DOIs
StatePublished - Jun 15 2005

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Refractory coccidioidomycosis treated with posaconazole'. Together they form a unique fingerprint.

  • Cite this

    Anstead, G. M., Corcoran, G., Lewis, J., Berg, D., & Graybill, J. R. (2005). Refractory coccidioidomycosis treated with posaconazole. Clinical Infectious Diseases, 40(12), 1770-1776. https://doi.org/10.1086/430303